FDA's final guidance on Real-Time Oncology Review has been in effect since November 2023, and the detail most sponsors still get wrong is the same one the draft left ambiguous in 2022: RTOR was never a lower bar for entry. It is a narrower one. The final version did not relax the draft's eligibility test — it replaced a vague design requirement with two concrete exclusions, and either one ends your candidacy before FDA looks at a single efficacy number.
What RTOR actually does
RTOR lets a sponsor submit completed sections of an application — datasets, analyses, specific modules — as they are finished, so FDA's review team can begin working through the oncology submission before the formal filing date rather than waiting for one complete package. That shortens the elapsed time between topline results and an approval decision, which is exactly why it matters for an accelerated pathway strategy built around speed to label. It does not, on its own, change the statutory standard of evidence FDA applies, and designation under Breakthrough Therapy or Priority Review is a separate determination — RTOR is a review mechanic, not an expedited-program designation.
The exclusions that decide eligibility
The final guidance organizes around three questions, and the third is where most real-world candidacies are actually won or lost:
- Does the evidence support substantial improvement, or expedited-program criteria? Clinical evidence from an adequate, well-controlled study must show the product may offer a substantial improvement over available therapy on a clinically relevant endpoint — or the application otherwise meets the bar for an existing priority review or other expedited pathway.
- Is the endpoint one the review team can interpret quickly? Overall survival and objective response rate are the clean cases. A novel composite endpoint, or one needing extensive statistical justification, works against RTOR even with a strong result, because the whole premise is a review team that can assess data as it arrives.
- Is any part of the submission likely to need a longer review? This is the exclusion that actually filters candidates. If the product is expected to need a new REMS, or the review division expects to convene an advisory committee meeting, the application is out — full stop, regardless of how the efficacy data reads.
RTOR does not reward the strongest data. It rewards the cleanest submission — the one with nothing attached that could slow the review down. Why the third criterion decides most candidacies
How sponsors actually get in
Eligibility is not a box a sponsor checks on a submission form. It is an agreement a sponsor reaches with the review division, and the timing matters: candidacy is typically raised through the application's regulatory project manager around the time topline results from the pivotal trial are available — before the full dataset is locked and well before a planned filing date. Waiting until the application is complete to raise RTOR defeats the purpose, since the program's value is in reviewing components as they are finished, not in compressing a finished package. Sponsors running a cell or gene therapy oncology program should note that FDA's final guidance explicitly declined to extend RTOR to that class of products; CBER's review timelines follow a separate track, and assuming RTOR eligibility there is a planning error worth catching early.
- Clear the exclusion screen first. Confirm no new REMS and no advisory committee meeting is expected before investing in the RTOR case.
- Pressure-test the endpoint. Favor overall survival or response rate; flag novel or composite endpoints as a risk to candidacy, not just to the statistical analysis plan.
- Engage the review division early. Raise RTOR with the regulatory project manager around topline results, not at the planned filing date.
- Plan the submission as rolling, not singular. Once FDA agrees, structure components to the review division's schedule rather than one filing event.
None of this changes the underlying evidentiary bar. RTOR compresses the calendar between topline data and a decision; it does not substitute for a well-controlled trial or a defensible endpoint. The sponsors who lose RTOR candidacy late — after planning around it — are almost always the ones who treated the REMS and advisory-committee questions as downstream concerns rather than the gating ones they actually are.
Frequently asked questions
What disqualifies an application from the RTOR program?
FDA's final guidance excludes any application where some part of the submission is likely to need a longer review — most commonly because the product will require a new Risk Evaluation and Mitigation Strategy or an advisory committee meeting. Either one takes the application out of RTOR regardless of how strong the efficacy data looks.
Do RTOR endpoints have to be overall survival?
No, but they must be easily interpreted. Overall survival and objective response rate qualify readily; a novel composite endpoint, or one requiring extensive statistical explanation, works against RTOR even when the underlying result is strong, because the review team needs to assess it quickly against preliminary data.
How does a sponsor request RTOR participation?
RTOR is not self-declared on a submission form. Sponsors raise it with the review division, typically through the assigned regulatory project manager, around the time topline results from the pivotal trial are available — before the full dataset is locked, not after.
Sources & further reading
- FDA. Real-Time Oncology Review; Guidance for Industry (final, Nov. 8, 2023), 88 FR 77096, Docket FDA-2022-D-0823. federalregister.gov
- FDA. Real-Time Oncology Review (RTOR) — Oncology Center of Excellence program overview. fda.gov
This article is provided for general informational purposes and reflects the regulatory landscape as of November 2026. It is not legal or regulatory advice. Confirm current RTOR eligibility criteria and program scope with FDA or qualified counsel before acting.